<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="[[HPV+ OPSCC incidence over time]]
  &ldquo;&mldr;overall HPV prevalence in OPSCC is increasing significantly over time:
  from 40."><title>Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://notes.beauhilton.com//icon.png><link href=https://notes.beauhilton.com/styles.708c2658f93e3a9d323a1f9fded8f4b2.min.css rel=stylesheet><link href=https://notes.beauhilton.com/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://notes.beauhilton.com/js/darkmode.1335f8cd6fd9b40f9a19de794cc0db9e.min.js></script>
<script src=https://notes.beauhilton.com/js/util.9825137f5e7825e8553c68ce39ac9e44.min.js></script>
<link rel=stylesheet href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script src=https://notes.beauhilton.com/js/popover.9b72b70bd35617d0635e9d15463662b2.min.js></script>
<script src=https://notes.beauhilton.com/js/code-title.b35124ad8db0ba37162b886afb711cbc.min.js></script>
<script src=https://notes.beauhilton.com/js/clipboard.c20857734e53a3fb733b7443879efa61.min.js></script>
<script src=https://notes.beauhilton.com/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const BASE_URL="https://notes.beauhilton.com/",fetchData=Promise.all([fetch("https://notes.beauhilton.com/indices/linkIndex.28a1d7cbad855c627abfe24ff4719320.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://notes.beauhilton.com/indices/contentIndex.ce5efaccb5a2f9daed029cfd93582cf9.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://notes.beauhilton.com",!0,!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!0;drawGraph("https://notes.beauhilton.com",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/notes.beauhilton.com\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://notes.beauhilton.com/js/full-text-search.24827f874defbbc6d529926cbfcfb493.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://notes.beauhilton.com/>üèïÔ∏è notes</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer</h1><p class=meta>Last updated
Dec 9, 2022
<a href=https://github.com/cbeauhilton/quartz/tree/hugo/content/reference/@vermorkenWhereWhenUse2021.md rel=noopener>Edit Source</a></p><ul class=tags></ul><ul><li><p><a class="internal-link broken">HPV+ OPSCC incidence over time</a></p></li><li><p>&ldquo;&mldr;overall HPV prevalence in OPSCC is increasing significantly over time:</p></li><li><p>from 40.5% before 2000,
to 64.3% between 2000 and 2004,
and 72.2% between 2005 and 2009&rdquo;</p></li><li><p>&ldquo;age at OPSCC diagnosis is increasing for both HPV-positive and HPV-negative patients, and a rising proportion of older patients have HPV-positive tumors&rdquo;</p></li><li><p>[[OPSCC HPV+ survival ]]</p></li><li><p>overall, HPV+ OPSCC has better outcomes than HPV- OPSCC</p></li><li><p>age matters: HPV+ pts >=70yo have similar survival to HPV- pts 50-59yo</p></li><li><p><a class="internal-link broken">HNSCC timeline of therapies</a></p></li><li><p>1960s: MTX for recurrent or metastatic disease</p></li><li><p>1970s, early: <a class="internal-link broken">MTX</a> vs <a class="internal-link broken">cisplatin</a> as part of a combined approach for stage IV, M1, recurrent w/o option for salvage</p><ul><li>cisplatin single-agent RR 14-41% (higher if prev untx)</li></ul></li><li><p>1970s, late: cisplatin+<a class="internal-link broken">bleomycin</a>, then added MTX or <a class="internal-link broken">vinca_alkaloids</a>, then progressed to cisplatin+<a class="internal-link broken">5-FU</a></p><ul><li>1977 Wayne State started a series of pilot studies, non-RCT:</li><li>prev untx, cisplatin+<a class="internal-link broken">vincristine</a>+bleomycin, RR 80%, CR 29%.</li><li>bc bleomycin had so much pulm tox and cis+5-FU (<a class="internal-link broken">CF_PF</a>) was the new hotness, follow-up study used CF (2 cycles, C 100mg/m2 D1, F 1000mg/m2/day x96h): RR 88%, CR 19%.</li><li>CF regimen then changed to run over 120h (another 1g of F) and 3 cycles: RR 93%, CR 38%</li><li>final CF regimen repeated by Radiation Therapy Oncology Group (<a class="internal-link broken">RTOG</a>): RR 86%, CR 38%.</li><li>next study tried to increase cisplatin, but no benefit was shown</li></ul></li><li><p>1980s (1979-1987):</p><ul><li>5x RCT w MTX, 4/5 -ve for survival<ul><li>1/5 +ve: gave <a class="internal-link broken">intra-arterial</a> MTX, benefit only present in stage II oral cavity cancer</li></ul></li><li>other RCTs done, all -ve (again other than one study, a different one, that also used intra-arterial chemo and only showed benefit in oral cavity cancer)</li><li>noted that pts who responded well to chemo also responded well to RT</li></ul></li><li><p>1990s: <a class="internal-link broken">CCRT</a></p><ul><li>this paper uses CCRT to mean, specifically, &ldquo;Concurrent Cisplatin-based chemoRadiotherapy&rdquo;</li><li>CCRT used adjuvantly for unfavorable surgical results (R+, extracapsular extension), definitively for unresectable disease</li></ul></li><li><p>2000s: targeted therapy, IO, <a class="internal-link broken">taxanes</a></p><ul><li>two main RCTs, one in US and one in Europe, added <a class="internal-link broken">docetaxel</a> == <a class="internal-link broken">TPF</a></li><li>TPF worked better than PF (see image below), more tolerable, cost-effective.</li><li>~75% completed TPF+RT per protocol, ~25% had treatment delays during TPF</li><li>did not answer whether <a class="internal-link broken">ICT</a>+CCRT vs CCRT alone is better, and incidences of toxicities with ICT+CCRT is higher than with CCRT alone (febrile 11%, &ldquo;toxic death&rdquo; up to 6%)</li><li>European TPF (<a class="internal-link broken">TAX323_EORTC24971</a>):<ul><li>3 cycles</li><li>docetaxel 75mg/m2 x1</li><li>cisplatin 75mg/m2 x1</li><li>5-FU 750mg/m2/day x5d (3750mg)</li><li>only prev untx, unresectable LA-HNSCC</li><li>RT afterward (4-7wks) if no disease progression, dealer&rsquo;s choice RT protocol (66-74 Gy in various fractionation schema)</li><li>Resection before or after RT, dealer&rsquo;s choice and clinical situation</li></ul></li><li>American TPF (<a class="internal-link broken">TAX324</a>):<ul><li>4 cycles</li><li>docetaxel 75mg/m2 x1</li><li>cisplatin 100mg/m2 x1</li><li>5-FU 1000mg/m2/day x4d (4000mg)</li><li>prev untx, unresectable/low likelihood of surgical cure, and pts who were candidates for organ preservation</li><li>CCRT afterward (3-8wks), 70-74Gy + carbo AUC 1.5 x7wks</li><li>Resection 6-12wk s/p CCRT if resectable disease (e.g. not CR)</li></ul></li></ul><p><img src=/files/TAX324_TAX323_20221209151920.png width=auto></p><pre><code>  - because of increased toxicities with TPF, modified regimens have been tried:
  	- <a class="internal-link broken">modified TPF</a>: Fayette J, Fontaine-Delaruelle C, Ambrun A, et¬† al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in¬†locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget. 2016;7:37297‚Äì304.
  	- <a class="internal-link broken">weekly carbo+taxol</a>: Herman LC, Chen L, Garnett A, et¬† al. Comparison of carboplatin-paclitaxel to docetaxelcisplatin-5-fluorouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014;50:52‚Äì8.
  	- <a class="internal-link broken">TPEx</a> (cisplatin, docetaxel, cetuximab): Zenda S, Ota Y, Kiyota N, et¬†al. A multicenter phase II trial of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for patients with local advanced squamous cell carcinoma of the head and neck (CSPOR HN01: ECRIPS study). Front. Oncologia. 2019;9:6.
</code></pre></li><li><p><a class="internal-link broken">ICT LA-HNSCC indications</a></p><ul><li>larynx preservation</li><li>treatment intensification (?)</li><li>borderline resectable or unresectable <em>oral cavity</em> cancer</li><li>selection tool for RT dose de-escalation in HPV+ OPSCC</li><li>oligometastatic disease</li></ul></li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/notes/HPV+-OPSCC-incidence-over-time/ data-ctx=reference/@vermorkenWhereWhenUse2021 data-src=/notes/HPV+-OPSCC-incidence-over-time class=internal-link>HPV+ OPSCC incidence over time</a></li></ul></div><div><script src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://notes.beauhilton.com/js/graph.abd4bc2af3869a96524d7d23b76152c7.js></script></div></div><div id=contact_buttons><footer><p>Made by beau hilton using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, ¬© 2022</p><ul><li><a href=https://notes.beauhilton.com/>Home</a></li><li><a href=https://beauhilton.com>beauhilton.com</a></li><li><a href=https://github.com/cbeauhilton>Github</a></li></ul></footer></div></div></body></html>